The FDA Accepts For Review Beigene's Tislelizumab Application As First Line Treatment Of Unresectable, Locally Advanced Or Metastatic Esophageal Squamous Cell Carcinoma, Target Action Date In 2H Of 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted for review Beigene's application for Tislelizumab as a first line treatment for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma. The target action date is set for the second half of 2024.
September 19, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Beigene's Tislelizumab application acceptance by the FDA could potentially boost the company's stock in the short term.
The FDA's acceptance of Beigene's Tislelizumab application for review is a positive development for the company. This could potentially lead to an increase in the company's stock price in the short term as it indicates progress in the company's product pipeline and potential future revenue streams.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100